Kurs & Likviditet
|Lista||First North Stockholm|
|Industri||Läkemedel & Handel|
|2023-01-12||Ordinarie utdelning NEWBRY 0.00 SEK|
Newbury Pharmaceuticals AB has successfully entered the Swedish and Norwegian market by making its first product available to patients and prescribers. It is the first launch and thereby an important milestone in validating the business model.
“Making Icatibant Newbury available in Sweden and Norway is an important milestone to Newbury as we see the fruits of the seeds sown. We expect to see more products being launched this year and to harvest some of these fruits during second half of 2022 and 2023 with an ambition of growing the business continuously.” Says Mr. Lars Minor, CEO of Newbury.
Sales uptake will start later due to tendering processes and Newbury will report on sales in future Quarterly reports.
Icatibant Newbury is indicated for the treatment of acute attacks of hereditary angioedema in adults. The product is a portable acute therapy option that can go wherever patients go, so patients are always prepared to treat an attack, if needed. Icatibant Newbury is supplied as a 3-ml, pre-filled syringe and is administered by patients in the abdomen or stomach.
Icatibant Newbury relates to a product in the field of rare diseases. Rare diseases are characterized by few patients and relatively high treatment costs due to the complexity and low prevalence of the disease. Newbury has four products within this category from the total of 27 products in the portfolio.